Sunday, November 18, 2018
News

Alembic Pharma gets tentative USFDA nod for Ticagrelor tablets

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Thursday, Jul 12 2018 IST
Pharma Major, Alembic Pharmaceuticals said that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abberivated New Drug Application(ANDA) Ticagrelor tablets 90 mg.

The tentatively approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product (RLD), Brilinta tablets of Astrazeneca Pharmaceuticals LP.

It is used to reduce the rate of cardiovascular death and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).

Quoting IQVIA sales data, the company said, Ticagrelor tablets, 90 mg had an estimated market size of USD625 million for 12 months, ending December 2017.

The company said it now has a total of 75 ANDA approvals from the USFDA.

UNI JS NV SM SDR 1440

-- (UNI) -- C-1-DL0171-1435611.Xml

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
6 dead in truck-car collision...
Rahul challenges PM Modi for debate over...
Nagapattinam: Residents bear brunt of cy...
Ajay Bhushan Pandey appointed new revenu...
Sex education before college lowers risk...
INLD's Adhikar Yatra from Dec 1 for SYL ...
More...    
 
 Top Stories
Hugh Grant says fatherhood is chaos... 
Trump administration denies reachin... 
'18 Syrian troops killed in attack ... 
Nepal: 3 educational institutions s... 
Motherhood has changed Cheryl Tweed... 
Argentine govt admits it lacks mean... 
6 dead in truck-car collision... 
Nagapattinam: Residents bear brunt ...